The Mesoblast limited (ASX: MSB) share price was out of action on Thursday and missed out on the S&P/ASX 200 Index (ASX: XJO) rebound following a trading halt request prior to the market open.
Why is the Mesoblast share price in a trading halt?
This morning the biotech company requested a trading halt pending the release of an announcement.
That announcement relates to the United States Food and Drug Administration’s review of its Biologics License Application for RYONCIL (remestemcel-L). Mesoblast is seeking approval for its use in treating paediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD).
The United States Food and Drug Administration gave its priority review date of 30 September but appears to be either behind schedule or taking its time with the review.
Priority reviews are given to drugs treating serious conditions with the potential to provide significant improvements in safety or effectiveness over existing therapies. They traditionally cut the time in which the administration aims to take action on a drug’s application from ten months to six.
What are the chances of success?
Going into the review, Mesoblast was well-placed to gain approval thanks to its meeting with the Oncologic Drugs Advisory Committee of the Food and Drug Administration in August.
At the meeting, the Committee voted overwhelmingly (9 to 1) in favour that the available data supports the efficacy of remestemcel-L in paediatric patients with SR-aGvHD.
This was a big win the company, as the ODAC plays a key role in whether certain drugs get approval or not. Failure to gain the support of the ODAC would make it almost impossible to then gain FDA approval.
What now?
Mesoblast requested that the trading halt continues until it makes its announcement. This is expected to be on Monday 5 October 2020.
This could be an indication that it expects the Food and Drug Administration to make its decision on Friday night (Australian time).
These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- ASX 200 up 1.6%: CBA higher on COVID-19 loan deferrals update, Reliance rockets
- 5 things to watch on the ASX 200 on Thursday
- ASX 200 ends the day flat, BOQ (ASX:BOQ) shares drop on impairments
- Why a2 Milk, Bank of Queensland, Mesoblast, & Northern Star are dropping lower today
- Is the Mesoblast (ASX: MSB) share price still good value?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Why the Mesoblast (ASX:MSB) share price is in a trading halt appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/33ilBf9
Leave a Reply